| Q47992798 | A Dynamic Model of Immune Responses to Antigen Presentation Predicts Different Regions of Tumor or Pathogen Elimination |
| Q26777111 | A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers |
| Q55004131 | A Tumor Profile in Primary Immune Deficiencies Challenges the Cancer Immune Surveillance Concept. |
| Q42150466 | A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition |
| Q37565031 | A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas |
| Q33940160 | A fresh look at tumor immunosurveillance and immunotherapy. |
| Q91639484 | A mathematical solution to Peto's paradox using Polya's urn model: implications for the aetiology of cancer in general |
| Q52745100 | A model of the role of natural killer cells in immune surveillance ? I |
| Q52712332 | A model of the role of natural killer cells in immune surveillance ? II |
| Q45242608 | A ten-year cervical-smear screening programme |
| Q36069288 | A test for mutation theory of cancer: Carcinogenesis by misrepair of DNA damaged by 4-nitroquinoline 1-oxide |
| Q58112581 | ASO Author Reflections: "From Computer to Bedside": A New Translational Approach to Immunogenomics |
| Q57056125 | Adoptive cell therapy against EBV-related malignancies: a survey of clinical results |
| Q42172986 | Aging, cancer, and cancer vaccines |
| Q64266717 | An Agent-based Model for Investigating the Effect of Myeloid-Derived Suppressor Cells and its Depletion on Tumor Immune Surveillance |
| Q45288287 | Aneuploidy theory explains tumor formation, the absence of immune surveillance, and the failure of chemotherapy |
| Q28390573 | Anti-tumor immunity: myeloid leukocytes control the immune landscape |
| Q38748641 | Antitumour actions of interferons: implications for cancer therapy |
| Q92796464 | Application of PD-1 Blockade in Cancer Immunotherapy |
| Q90480978 | Association between interleukin-36γ and tumor progression in non-small cell lung cancer |
| Q37727195 | Associations between allergies and risk of hematologic malignancies: results from the VITamins and lifestyle cohort study |
| Q26865509 | Beneficial autoimmunity at body surfaces - immune surveillance and rapid type 2 immunity regulate tissue homeostasis and cancer |
| Q58959552 | Biological Equilibria in Human Cancer |
| Q39777035 | Biological interactions of N-nitroso compounds: A review |
| Q37952245 | Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas |
| Q33960021 | Bridging innate and adaptive antitumor immunity targeting glycans. |
| Q24799074 | CAM and NK Cells |
| Q48185876 | CD4 and CD8 T lymphocyte interplay in controlling tumor growth |
| Q42277523 | CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice |
| Q50975027 | CD45RA-Foxp3high regulatory T cells have a negative impact on the clinical outcome of head and neck squamous cell carcinoma. |
| Q53594194 | Caffeine inhibits cell transformation by 4-nitroquinoline-1-oxide. |
| Q64898964 | Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors? |
| Q24605537 | Can tissue-based immune markers be used for studying the natural history of cancer? |
| Q33646584 | Cancer Immunoprevention and Public Health |
| Q37068312 | Cancer as an immune-mediated disease |
| Q34309399 | Cancer immunotherapy in clinical practice -- the past, present, and future. |
| Q37908998 | Cancer immunotherapy--revisited |
| Q38151738 | Cancer immunotherapy: accomplishments to date and future promise |
| Q39297560 | Cancer immunotherapy: are we there yet? |
| Q38288055 | Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking |
| Q35033249 | Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. |
| Q100464975 | Cancer progression and the invisible phase of metastatic colonization |
| Q35218626 | Cancer vaccines at an inflexion point: what next? |
| Q38032880 | Cancer vaccines: should we be targeting patients with less aggressive disease? |
| Q89609874 | Cancer-induced immunosuppression can enable effectiveness of immunotherapy through bistability generation: A mathematical and computational examination |
| Q55709806 | Cancer; an induced disease of twentieth century! Induction of tolerance, increased entropy and 'Dark Energy': loss of biorhythms (Anabolism v. Catabolism). |
| Q39965848 | Carcinogenic nitroso compounds |
| Q90255944 | Cardiorenal complications of immune checkpoint inhibitors |
| Q34503803 | Cell-Mediated Immune Responses of Preleukemic AKR Mice. |
| Q39944336 | Cell-Mediated Immunity to Tumor Cells |
| Q27025873 | Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma |
| Q38400420 | Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology |
| Q37693490 | Chronic Inflammation: Synergistic Interactions of Recruiting Macrophages (TAMs) and Eosinophils (Eos) with Host Mast Cells (MCs) and Tumorigenesis in CALTs. M-CSF, Suitable Biomarker for Cancer Diagnosis! |
| Q41046354 | Coexistence of leukemic reticuloendotheliosis and histiocytic lymphoma:A case report |
| Q34582640 | Combinations of immunotherapy and radiation in cancer therapy. |
| Q39795945 | Comparative toxicology of N-nitroso compounds and their carcinogenic potential to man |
| Q37761395 | Contribution of the Morris Hepatomas to the Biochemistry of Cancer — Establishment of the Phenotypic Heterogeneity of Neoplasms In Vivo |
| Q27004733 | Control of the immune response by pro-angiogenic factors |
| Q72816131 | Correlative histochemical and histological studies on thirty radical prostatectomy specimens |
| Q37046631 | Cross-platform comparison of independent datasets identifies an immune signature associated with improved survival in metastatic melanoma |
| Q39189908 | Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines |
| Q40561381 | Cutting Edge: IgE Plays an Active Role in Tumor Immunosurveillance in Mice. |
| Q54959954 | DNA methylation signatures of breast cancer in peripheral T-cells. |
| Q104617818 | Deceptology in cancer and vaccine sciences: Seeds of immune destruction-mini electric shocks in mitochondria: Neuroplasticity-electrobiology of response profiles and increased induced diseases in four generations - A hypothesis |
| Q27325140 | Development and characterization of a preclinical model of breast cancer lung micrometastatic to macrometastatic progression |
| Q90317070 | Development and characterization of mammary intraductal (MIND) spontaneous metastasis models for triple-negative breast cancer in syngeneic mice |
| Q47844202 | Dynamics of the cell-mediated immune response to tumour growth. |
| Q69637428 | Effects of DDT on the calcium transport and thymidine uptake of bovine lymphocytes |
| Q52596335 | Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. |
| Q37916077 | Epithelial delamination and migration: lessons from Drosophila |
| Q59356682 | Etiology of increased cancer incidence after solid organ transplantation |
| Q51151461 | Evolved Dependence in Response to Cancer. |
| Q35022833 | Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) |
| Q35140467 | Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology. |
| Q50025193 | From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift? |
| Q91735135 | Genetic and molecular biology of breast cancer among Iranian patients |
| Q37632159 | Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy |
| Q64903231 | Gut dysbiosis: a potential link between increased cancer risk in ageing and inflammaging. |
| Q35621786 | HLA-G in melanoma: can the current controversies be solved? |
| Q91543835 | Haploinsufficiency of UNC13D increases the risk of lymphoma |
| Q39014465 | Hide-and-seek: the interplay between cancer stem cells and the immune system |
| Q38289426 | How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances |
| Q34418112 | How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules? |
| Q28831392 | IL-13 from intraepithelial lymphocytes regulates tissue homeostasis and protects against carcinogenesis in the skin |
| Q34305014 | Iatrogenic alterations of immunologic surveillance in man and their influence on malignancy |
| Q50856757 | IgG Glycome in Colorectal Cancer. |
| Q36517706 | Immune cell recruitment and cell-based system for cancer therapy |
| Q45871487 | Immune checkpoint inhibitors in cancer therapy |
| Q49859661 | Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers |
| Q41146259 | Immune response: Self-foreignness |
| Q93229462 | Immunoediting is not a primary transformation event in a murine model of MLL-ENL AML |
| Q39365905 | Immunologic approaches to the diagnosis of cancer |
| Q37748469 | Immunologic mechanisms in RCC and allogeneic renal transplant rejection. |
| Q37039588 | Immunological aspects of cancer chemotherapy |
| Q42366660 | Immunological consequences of ageing microvascular hemodynamic changes in view of cancer development and treatment |
| Q36167785 | Immunological ignorance of solid tumors |
| Q33967542 | Immunology, virology, and cancer |
| Q40108318 | Immunopathology induced by the feline leukemia virus |
| Q39120161 | Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go? |
| Q38752191 | Immunotherapy and radiation in glioblastoma. |
| Q48194503 | Immunotherapy as an Option for Cancer Treatment. |
| Q38367414 | Immunotherapy for lung cancer: for whom the bell tolls? |
| Q38959645 | Immunotherapy for prostate cancer: False promises or true hope? |
| Q33709232 | Immunotherapy for solid tumors--a review for surgeons |
| Q27010472 | Immunotherapy in gastric cancer |
| Q38014084 | Immunotherapy in nonmelanoma skin cancer |
| Q38156029 | Impact of anesthesia for cancer surgery: Continuing professional development. |
| Q28607232 | Impaired gp100-Specific CD8(+) T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model |
| Q36334894 | In vitro induction of tumor-specific immunity. I. Parameters of activation and cytotoxic reactivity of mouse lymphoid cells immunized in vitro against syngeneic and allogeneic plasma cell tumors |
| Q37708187 | Interactions between the immune system and cancer: a brief review of non-spatial mathematical models |
| Q95491344 | Introduction |
| Q47110491 | Is There an Opportunity for Current Chemotherapeutics to Up-regulate MIC-A/B Ligands? |
| Q52353493 | Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses. |
| Q84947318 | Loss of Gastro-intestinal-specific Antigen in Neoplasia |
| Q36663622 | Lymphopenia and its association with survival in patients with locally advanced cervical cancer |
| Q36714774 | MHC class I antigens and immune surveillance in transformed cells. |
| Q92364680 | MHC/HLA Class I Loss in Cancer Cells |
| Q41193824 | Malignant lymphoma and extensive viral wart formation in a patient with intestinal lymphangiectasia and lymphocyte depletion |
| Q34425671 | Malignant tumors arising de novo in immunosuppressed organ transplant recipients |
| Q34125697 | Methodological issues for determining intervals of subsequent cancer screening |
| Q50117508 | MiRNAs at the Crossroads between Innate Immunity and Cancer: Focus on Macrophages |
| Q41195876 | Mismatch repair as a source of mutations in non-dividing cells |
| Q92879135 | Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression |
| Q39770020 | Natural Cell-Mediated Immunity |
| Q49724715 | Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review. |
| Q97519699 | Natural Selection on Exonic SNPs Shapes Allelic Expression Imbalance (AEI) Adaptability in Lung Cancer Progression |
| Q35300077 | New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape |
| Q34331993 | New roads open up for implementing immunotherapy in mesothelioma |
| Q37877162 | Non-cell-autonomous tumor suppression: oncogene-provoked apoptosis promotes tumor cell senescence via stromal crosstalk. |
| Q38885490 | Noncoding RNAs in Cancer Immunology. |
| Q38637906 | Novel avenues in immunotherapies for colorectal cancer |
| Q26770780 | Novel technologies and emerging biomarkers for personalized cancer immunotherapy |
| Q69814985 | Occurrence of cancer in immune deficiencies |
| Q39949097 | Organ Transplantation and Cancer |
| Q28260529 | POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer |
| Q47600992 | Pathways of tumor development and progression in drug-induced nonmelanoma skin cancer: a new hope or the next great confusion? |
| Q82771009 | Polymorphisms in the TLR6 gene associated with the inverse association between childhood acute lymphoblastic leukemia and atopic disease |
| Q91644592 | Primary Immunodeficiencies and Oncological Risk: The Experience of the Children's Hospital of Brescia |
| Q35043113 | Principles of tumor immunosurveillance and implications for immunotherapy |
| Q39866302 | Problems in the study of oncogens in vitro |
| Q64949142 | Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Conditional Factors in Localized Pancreatic Ductal Adenocarcinoma Patients. |
| Q57167306 | Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer |
| Q37983730 | Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy |
| Q41464689 | Psychological enquiry: a contribution to cancer research |
| Q33606144 | Rational combinations of immunotherapeutics that target discrete pathways |
| Q39329364 | Regional immunotherapy for liver and peritoneal metastases |
| Q84073243 | Regulatory T cells in cancer |
| Q38149916 | Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions |
| Q98613073 | Resolving Peto's paradox: Modeling the potential effects of size-related metabolic changes, and of the evolution of immune policing and cancer suppression |
| Q34666066 | Review: cancer-induced autoimmunity in the rheumatic diseases |
| Q24805285 | Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy |
| Q33732986 | Revisiting the hallmarks of cancer |
| Q74292264 | Role of natural killer cells and T cells in immune surveillance |
| Q38927173 | Sarcoid-like lymphadenopathy in malignant teratoma |
| Q38207986 | Sarcoma immunotherapy: past approaches and future directions |
| Q37574026 | Self-reported prior lung diseases as risk factors for non-small cell lung cancer in Mexican Americans. |
| Q33762632 | Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis |
| Q54404821 | Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence |
| Q53535126 | Synergistic modulation of lymphocyte mitogenesis by carcinogenic xenobiotics. |
| Q90312347 | Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward? |
| Q39044981 | Targeting cancer-related inflammation in the era of immunotherapy |
| Q37000638 | Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies |
| Q47252754 | The Role of Tumor Microenvironment in Cancer Immunotherapy. |
| Q26750877 | The Sweet Side of Immune Evasion: Role of Glycans in the Mechanisms of Cancer Progression |
| Q47603527 | The coming of age of tumour immunotherapy |
| Q28073937 | The concept of immune surveillance against tumors. The first theories |
| Q38288116 | The delicate balance of melanoma immunotherapy |
| Q96576393 | The emerging role of cancer cell plasticity and cell-cycle quiescence in immune escape |
| Q55301251 | The evolving understanding of immunoediting and the clinical impact of immune escape. |
| Q33660069 | The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. |
| Q90003208 | The multifaceted immune regulation of bladder cancer |
| Q54980315 | The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. |
| Q57278479 | Therapeutic Impact of Immune Responses in Cancer |
| Q59800417 | Tissue Resident CD8 Memory T Cell Responses in Cancer and Autoimmunity |
| Q34484042 | Translating tumor antigens into cancer vaccines |
| Q39128240 | Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment |
| Q49434203 | Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer |
| Q36342830 | Tumor necrosis serum induces a serologically distinct population of NK cells |
| Q36997144 | Tumor stress, cell death and the ensuing immune response. |
| Q26999306 | Tumor-primed NK cells: waiting for the green light |
| Q39744314 | Unspecific cellular immunity before therapy in patients with squamous cell carcinoma of head and neck |
| Q33783609 | Vaccine prevention of cancer: can endogenous antigens be targeted? |
| Q39763261 | Xeroderma pigmentosum: genetic and environmental influences in skin carcinogenesis |
| Q85076205 | [Prostate carcinoma: vaccination as a new option for treatment] |
| Q92588804 | mTOR and Aging: An Old Fashioned Dress |